RamiSalah-EddinKomrokjiMD

Hematologic Oncology

Professor of Oncologic Sciences

Overview of Dr. Komrokji

Dr. Rami Komrokji is a hematologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from University of Jordan Faculty of Medicine and has been in practice 15 years. He specializes in hematologic oncology and is experienced in hematologic oncology, namely acute myeloid leukemia, Myelodysplastic syndromes, and myeloproliferative neoplasm. He is member of NCCN MDS committee. He has authored more than 200 peer reviewed papers and lectured world wide about those diseases.

Office
12902 magnolia drive
Tampa
Tampa, FL 33612
Book by Phone+1(610) 486-3729

Education & Training

University of RochesterFellowship, Hematology and Medical Oncology, 2001 - 2004
St Vincent Charity Medical CenterResidency, Internal Medicine, 1999 - 2001
Columbia Saint Luke's Medical CenterResidency, Internal Medicine, 1998 - 1999
University of Jordan Faculty of MedicineClass of 1996

Certifications & Licensure

FL State Medical License 2008 - 2025
OH State Medical License 1999 - 2016
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Top publication award clinical science H Lee Moffitt Cancer Center & Research Institute, 2015
America's Top Doctors Castle Connolly, 2012-2014
America's Top Doctors for Cancer Castle Connolly, 2011-2013

Clinical Trials

Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma Start of enrollment: 2003 Aug 27
Completed
Phase 3
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia Start of enrollment: 2007 Nov 15
Completed
Phase 2
A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia Start of enrollment: 2007 Nov 01
Withdrawn
Phase 2
A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis Start of enrollment: 2008 Aug 01
Completed
Phase 1, Phase 2
A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome Start of enrollment: 2009 Jun 01
Completed
Phase 1
CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML) Start of enrollment: 2009 Aug 01
Completed
Phase 2
Erlotinib Study for Myelodysplastic Syndrome (MDS) Start of enrollment: 2009 Sep 01
Completed
Phase 2
Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome Start of enrollment: 2009 Dec 01
Completed
Phase 1
Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS Start of enrollment: 2010 Apr 28
Completed
Phase 2
Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia Start of enrollment: 2011 Apr 06
Terminated
Phase 1
A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes Start of enrollment: 2012 Jan 01
Completed
Phase 1
Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL Start of enrollment: 2012 Mar 30
Active, not recruiting
Phase 2
Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients Start of enrollment: 2013 Feb 21
Completed
Phase 1
Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) Start of enrollment: 2012 Nov 28
Completed
Phase 2
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib Start of enrollment: 2013 Feb 20
Completed
Phase 1, Phase 2
Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS) Start of enrollment: 2013 Jul 01
Completed
Phase 2
Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) Start of enrollment: 2013 Aug 29
Completed
Phase 2
Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome Start of enrollment: 2013 Jun 01
Completed
Phase 2
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL Start of enrollment: 2014 Jun 01
Terminated
Phase 2
A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS) Start of enrollment: 2014 Sep 01
Terminated
Phase 1
A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML Start of enrollment: 2015 Jun 18
Completed
Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Start of enrollment: 2019 Apr 01
Recruiting
Phase 1, Phase 2
PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS Start of enrollment: 2019 May 20
Recruiting
Phase 1
Quality of Life Model for Older Patients With AML Start of enrollment: 2020 Jul 08
Active, not recruiting
CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML Start of enrollment: 2021 Jan 14
Active, not recruiting
Phase 1, Phase 2
Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA Start of enrollment: 2021 Mar 30
Recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

93 citations
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort
Maximilian Stahl, Michelle DeVeaux, Theo de Witte, Judith Neukirchen, Mikkael A. Sekeres
Blood Advances. 2018-07-24
200 citations
Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study
Nancy K. Gillis, Markus Ball, Qing Zhang, Zhenjun Ma, YuLong Zhao
The Lancet. Oncology. 2017-01-01
265 citations
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes.
David A. Sallman, Amy E. DeZern, Guillermo Garcia-Manero, David P. Steensma, Gail J. Roboz
Journal of Clinical Oncology. 2021-01-15

Journal Articles

Mutational Landscape of myelodysplastic/myeloproliferative Neoplasm – Unclassifiable (MDS/MPN-U)
Aziz Nazha, Rami S Komrokji, Andrew Sochacki, Mikkael A Sekeres, Prithviraj Bose, Courtney D DiNardo, Hagop M Kantarjian, Srdan Verstovsek, Sanam Loghavi, Jaroslaw P M..., Blood

Abstracts/Posters

Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia
Rami S. Komrokji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical State
Rami S. Komrokji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Bromodomain and Extra Terminal Domain (BET) Inhibitors Sensitize Chronic Myelomonocytic Leukemia (CMML) to PIM Inhibition Via Downregulation of Mir-33a
Rami S. Komrokji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (...
Rami S. Komrokji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Timing for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myelomonocytic Leukemia (CMML): A Joint Study from the International MDS/MPN Working Gr...
Rami S. Komrokji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes
Rami S. Komrokji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Resul...
Rami S. Komrokji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Marrow Ring Sideroblasts Are Highly Predictive for TP53 Mutation in MDS with Excess Blasts
Rami S. Komrokji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)
Rami S. Komrokji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia
Rami S. Komrokji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome
Rami S. Komrokji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
Rami S. Komrokji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase 1 Study of Lenzilumab, a humaneered recombinant Anti_Human Granulocyte-Macrophage Colony- Stimulating Factor (anti-hGM-CSF) Antibody, for Chronic Myelomonocyti...
Rami S. Komrokji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms
Rami S. Komrokji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation
Rami S. Komrokji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study
Rami S. Komrokji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patient...
Rami S. Komrokji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis
Rami S. Komrokji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Comparison of Overall Responses after Standard Induction with High Dose Daunorubicin Versus Standard Dose Daunorubicin with Gemtuzumab Ozogamicin in Favorable Risk Acu...
Rami S. Komrokji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Overview of Primary and Secondary Myelofibrosis in Young Adults: Genomic Characteristics, Treatment Strategies and Outcomes
Rami S. Komrokji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell Transplantation
Rami S. Komrokji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (_60 Years Old) with Ac...
Rami S. Komrokji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax
Rami S. Komrokji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
CSF3R Mutations Are Exceedingly Rare Genetic Events Associated with Inferior Survival and Sensitivity to Ruxolitinib across Myeloid Malignancies
Rami S. Komrokji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Patient Derived Xenografts (PDX) Recapitulate Ruxolitinib Clinical Trial Responses and Identify a Novel Combination Therapy for Chronic Myelomonocytic Leukemia (CMML)
Rami S. Komrokji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

MPN Tumor Board: Application of Novel Agents for the Treatment of Polycythemia Vera and Myelofibrosis
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
SF3B1 Clone Size Is an Independent Determinant for Overall Survival and Response to Treatment in Patients with Myelodysplastic Syndrome
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Geno-Clinical Model to Aid in the Diagnosis of Myelodysplastic Syndrome (MDS) Versus Chronic Myelomonocytic Leukemia (CMML)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Increased Frequency of IDH1/2 Mutations in Extramedullary Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Clonal Suppression of TP53 Mutant MDS and Oligoblastic AML with Hypomethylating Agent Therapy Improves Overall Survival
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Validation of the Khorana Score in Acute Myeloid Leukemia Patients: A Single Institution Experience
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Ninth Annual Hematology Conference: An Update on Selected ASH Topics
The University of Tennessee Graduate School of Medicine, Knoxville, Tennessee - 1/19/2013
Join now to see all

Press Mentions

Geron Announces New Data to Be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO™ (Imetelstat) in Myeloid Hematologic MalignanciesNovember 5th, 2024
Geron Announces FDA Approval of RYTELO™ (Imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent AnemiaJune 6th, 2024
Geron (GERN) Q2 2020 Earnings Call TranscriptAugust 7th, 2020
Join now to see all

Committees

Member, NCCN MDS Guidelines committee 2008 - Present

Professional Memberships

American Society of Hematology - ASH
Member

Insurance Accepted

Aetna Choice POS II
Aetna HMO
AvMed Health Open Access
BCBS Blue Card PPO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
BCBS Kansas City Preferred-Care Blue PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Coventry Florida - Employer Group PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment